• 1
    Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation, and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439-1447.
  • 2
    Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
  • 3
    Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-1247.
  • 4
    Eapen CE, Nightingale P, Hubscher SG, Lane PJ, Plant T, Velissaris D, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci 2011;56:227-235.
  • 5
    Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell- derived ultra large vWF multimers under flow. Blood 2004;104:100-106.
  • 6
    Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008;6:1233-1235.
  • 7
    Manavalan JS, Hernandez L, Shah JG, Konikkara J, Naiyer AJ, Lee AR, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol 2010;71:50-57.
  • 8
    Mackie I, Eapen CE, Neil D, Lawrie AS, Chitolie A, Shaw JC, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH) is associated with sustained ADAMTS13 deficiency. Dig Dis Sci 2011;56:2456-2465.
  • 9
    Elias JE, Mackie I, Eapen CE, Chu P, Shaw JC, Elias E. Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency. J Hepatol 2012 Nov 10. doi:10.1016/j.jhep.2012.11.003.